Amiodarone and gynaecomastia share a clinically important association that every patient and prescriber should understand. Amiodarone is a class III antiarrhythmic medicine widely used across the UK to manage serious arrhythmias such as atrial fibrillation and ventricular tachycardia. Its complex pharmacology and significant iodine load mean it can disrupt thyroid function, which in turn may alter sex hormone balance and contribute to gynaecomastia — the benign enlargement of glandular breast tissue in males. This article explains the proposed mechanisms, how common this association may be, how it should be managed, and when to seek medical advice.

Can Amiodarone Cause Gynaecomastia?

Amiodarone can be associated with gynaecomastia, most plausibly through amiodarone-induced thyroid dysfunction rather than a direct oestrogenic drug effect; a direct mechanism is not well evidenced.

Amiodarone is a class III antiarrhythmic medicine widely used in the UK to manage serious cardiac arrhythmias, including atrial fibrillation and ventricular tachycardia. It works by prolonging the cardiac action potential and refractory period, primarily through blockade of potassium channels, though it also has sodium channel, calcium channel, and beta-blocking properties. Given its complex pharmacology and broad tissue distribution, amiodarone is associated with a wide range of adverse effects.

Gynaecomastia — the benign enlargement of glandular breast tissue in males — results from an imbalance between oestrogen and androgen activity at the breast tissue level. Gynaecomastia has been reported in patients taking amiodarone, predominantly in post-marketing case reports and is generally considered secondary to amiodarone-induced thyroid dysfunction rather than a direct drug effect. It is not consistently listed as a recognised adverse effect across all UK Summary of Product Characteristics (SmPCs); clinicians and patients should consult the current electronic Medicines Compendium (emc) SmPC for the specific product prescribed.

Amiodarone contains a high iodine load and interferes significantly with thyroid hormone synthesis and metabolism, causing both hypothyroidism and hyperthyroidism. Hypothyroidism, in particular, can alter sex hormone-binding globulin (SHBG) levels, raise prolactin, and disrupt sex hormone metabolism — changes that may contribute to gynaecomastia. Hyperthyroidism can also affect sex hormone balance and has been associated with gynaecomastia in some cases. Earlier suggestions that amiodarone might have a direct oestrogenic effect through structural resemblance to oestrogen precursors are not well evidenced and should not be relied upon as an established mechanism.

The frequency of amiodarone-associated gynaecomastia is not precisely known; available evidence is largely limited to case reports and post-marketing surveillance, and a reliable incidence figure cannot be stated with confidence. Patients and clinicians should be aware of this potential association, particularly in those on long-term therapy. If you suspect a side effect from amiodarone, you can report it via the MHRA Yellow Card scheme at https://yellowcard.mhra.gov.uk/.

How Common Is Gynaecomastia With Amiodarone?

The precise frequency is unknown; evidence comes mainly from case reports and post-marketing data, with no reliable incidence figure assigned in current UK SmPCs.

The precise frequency of gynaecomastia associated with amiodarone is unknown. It is not assigned a standard pharmacovigilance frequency category (such as 'uncommon') in current UK SmPCs, and published data are largely derived from case reports and post-marketing reports rather than controlled clinical trials. Clinicians should therefore treat any quoted incidence figures with caution.

Amiodarone-induced thyroid dysfunction is itself relatively common. British Thyroid Association guidance and published reviews indicate that clinically significant thyroid dysfunction — both hypothyroidism and hyperthyroidism — affects a meaningful proportion of patients on long-term amiodarone therapy, with estimates varying by iodine intake in the population studied. Because hypothyroidism is a recognised cause of gynaecomastia through its effects on SHBG and prolactin, patients who develop amiodarone-induced hypothyroidism may face a compounded risk. Regular thyroid function monitoring — as recommended in the BNF and by the Specialist Pharmacy Service (SPS) — is therefore important not only for thyroid health but also as an indirect safeguard against hormonally mediated side effects such as gynaecomastia.

Attributing causality solely to amiodarone can be challenging, as the medicine is most often prescribed to older men with multiple comorbidities — a population already at higher baseline risk of gynaecomastia from other causes. Gynaecomastia may also go unreported because patients feel embarrassed to raise the symptom, or clinicians may attribute it to other factors. Raising awareness among both patients and healthcare professionals is therefore an important aspect of safe prescribing and monitoring.

Managing Gynaecomastia in Patients Taking Amiodarone

Management begins with thyroid function tests; if hypothyroidism is confirmed, levothyroxine replacement may resolve gynaecomastia without changing the antiarrhythmic regimen.

The management of amiodarone-associated gynaecomastia begins with a thorough clinical assessment to identify the underlying cause. The first step is to check thyroid function tests (TFTs), as amiodarone-induced hypothyroidism is the most plausible intermediary mechanism. If hypothyroidism is confirmed, initiating or optimising levothyroxine replacement therapy may lead to gradual resolution of gynaecomastia over several months, without necessarily requiring a change in the antiarrhythmic regimen.

If thyroid function is normal, a broader assessment should be considered, including:

• Clinical examination — including examination of the testes to exclude a testicular mass

• Morning total testosterone and SHBG — to assess the androgen-to-oestrogen ratio

• Oestradiol — elevated levels may indicate peripheral aromatisation or an oestrogen-secreting tumour

• Prolactin — elevated levels can independently cause gynaecomastia

• LH and FSH — to evaluate gonadal axis function

• Liver function tests and renal function — hepatic or renal dysfunction can impair hormone metabolism

• Beta-hCG and AFP — these tumour markers should be checked if gynaecomastia is rapid in onset, progressive, or if a testicular abnormality is found, to exclude a germ cell tumour

If a testicular mass is identified or suspected, urgent scrotal ultrasound and urology referral are warranted. If breast examination reveals features suspicious for malignancy (see below), an urgent two-week wait referral to a breast clinic should be made in line with NICE NG12.

In cases where gynaecomastia is confirmed to be directly related to amiodarone and is causing significant discomfort or psychological distress, the treating cardiologist may consider whether an alternative antiarrhythmic agent is clinically appropriate. However, this decision must be made carefully, as amiodarone is often used when other options have failed or are contraindicated. Abrupt discontinuation of amiodarone carries serious cardiac risks and should never be undertaken without specialist guidance.

For persistent or severe gynaecomastia that does not resolve with management of the underlying cause, referral to an endocrinologist or breast surgeon may be warranted. Surgical options, such as subcutaneous mastectomy, are available in refractory cases, though these are rarely required. Tamoxifen has been used off-label in some cases of drug-induced gynaecomastia, but this should only be initiated by a specialist after reversible causes have been addressed; evidence in this specific context remains limited.

When to Speak to Your GP or Cardiologist

Patients should seek prompt medical advice for any new breast swelling or tenderness; features such as a hard lump, nipple discharge, or skin changes require an urgent two-week wait breast clinic referral.

Patients taking amiodarone who notice any swelling, tenderness, or enlargement of breast tissue should contact their GP or cardiologist promptly. Whilst gynaecomastia is generally a benign condition, it is important to rule out other causes — including, rarely, male breast cancer — particularly if the swelling is unilateral, hard, or fixed, or is associated with nipple discharge (especially if bloodstained) or skin changes such as dimpling or ulceration. These features should prompt an urgent two-week wait referral to a breast clinic in line with NICE guidance on suspected cancer (NG12), and should not be attributed to medication without proper clinical assessment.

You should seek medical advice if you experience:

• New or worsening breast swelling or tenderness

• Nipple discharge of any kind, particularly if bloodstained

• A hard, irregular, or fixed lump in the breast tissue

• Symptoms of thyroid dysfunction, such as unexplained weight gain, fatigue, cold intolerance, or constipation (suggesting hypothyroidism), or weight loss, palpitations, and heat intolerance (suggesting hyperthyroidism)

Routine monitoring whilst on amiodarone should be carried out in line with BNF and SPS guidance. This typically includes: a baseline chest X-ray before starting treatment; thyroid function tests and liver function tests every six months; a periodic ECG; and an ophthalmic review if visual symptoms develop. Further pulmonary assessment or chest imaging is recommended if respiratory symptoms arise that might suggest amiodarone-induced pulmonary toxicity — routine repeat chest X-rays and pulmonary function tests are not required in the absence of symptoms. If you are unsure whether your monitoring is up to date, your GP or pharmacist can review your records and arrange any outstanding tests.

It is essential that patients do not stop taking amiodarone without medical advice, even if they are concerned about side effects. Amiodarone controls potentially life-threatening heart rhythms, and stopping it abruptly could have serious consequences. Always discuss any concerns with your prescribing doctor before making any changes to your medication.

If you think you are experiencing a side effect from amiodarone, you can report it to the MHRA via the Yellow Card scheme at https://yellowcard.mhra.gov.uk/.

Other Medicines and Factors That May Contribute

Spironolactone, digoxin, antiandrogens, and several other medicines commonly prescribed to older men with cardiovascular disease are also recognised causes of gynaecomastia and should be reviewed alongside amiodarone.

When evaluating gynaecomastia in a patient taking amiodarone, it is important to consider that many other commonly prescribed medicines are also associated with this condition. In older men with cardiovascular disease — the typical amiodarone patient — polypharmacy is common, and multiple contributing factors may be present simultaneously.

Medicines with well-established or commonly recognised associations with gynaecomastia include:

• Spironolactone — frequently used in heart failure; acts as an anti-androgen and is one of the most common drug causes

• Antiandrogens (e.g., bicalutamide, flutamide) — used in prostate cancer

• 5-alpha-reductase inhibitors (e.g., finasteride, dutasteride) — used for benign prostatic hyperplasia and hair loss

• Digoxin — has weak oestrogenic activity

• Cimetidine — an H2-receptor antagonist with anti-androgenic properties

• Some antipsychotics (e.g., risperidone) — via hyperprolactinaemia

• Oestrogens, anabolic steroids, and exogenous testosterone — can cause gynaecomastia through aromatisation to oestrogen

• Certain antiretrovirals (e.g., efavirenz) — reported in clinical use

• Methadone and cannabis — associated in case reports and observational data

Some other medicines — including proton pump inhibitors, statins, ACE inhibitors, and calcium channel blockers — have been mentioned in case reports, but the evidence supporting a causal association is weak and these should not be considered established causes without further evaluation.

Beyond medication, several non-drug factors can independently cause or worsen gynaecomastia. These include obesity (adipose tissue converts androgens to oestrogens via aromatase), alcohol excess, liver cirrhosis, chronic kidney disease, hypogonadism, and natural hormonal changes associated with ageing. In many cases, gynaecomastia in older men is multifactorial, and amiodarone may be one of several contributing elements rather than the sole cause.

A careful structured medicines review — ideally conducted by a GP, clinical pharmacist, or specialist — can help identify whether any concurrent medicines could be substituted or deprescribed to reduce the overall hormonal burden. This holistic approach, rather than focusing on any single agent, is most likely to result in meaningful clinical improvement whilst maintaining the patient's cardiovascular safety. NICE CKS guidance on gynaecomastia provides a useful reference for clinicians undertaking this assessment.

Frequently Asked Questions